Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...

Fintel reports that on March 31, 2025, BTIG upgraded their outlook for Progyny (NasdaqGS:PGNY) from Neutral to Buy. Analyst ...

The S&P 500's recent breakdown below key technical levels suggests the market’s counter-trend rally may be over, said ...

BTIG analysts highlighted a historical trend suggesting a potential rebound for the S&P 500 (SPX) in April following a ...

BTIG says Rocket Companies (RKT) is acquiring Mr. Cooper (COOP) in an all-stock deal valuing Cooper at roughly $143 ore share, plus a $2 cash ...

BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in ...

BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the ...

Lululemon Athletica (NASDAQ:LULU – Free Report) had its price objective decreased by BTIG Research from $470.00 to $420.00 in ...

chief market technician at financial-services firm BTIG. In a March 28 note to clients, Krinsky pointed to the S&P 500's (SP500) inability to hold the 5,670 level, a gap that had been a key ...

On Monday, BTIG analysts maintained a Neutral rating on Venus Concept Inc. (NASDAQ:VERO) after the company reported lower-than-expected Q4 revenue. Venus Concept disclosed a quarterly revenue of $ ...